STREAMLINE HEALTH SOLUTIONS (STRM)

US86323X1063 - Common Stock

3.39  +0.24 (+7.62%)

After market: 3.22 -0.17 (-5.01%)

Fundamental Rating

1

Taking everything into account, STRM scores 1 out of 10 in our fundamental rating. STRM was compared to 37 industry peers in the Health Care Technology industry. Both the profitability and financial health of STRM have multiple concerns. STRM is valued expensive and it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

STRM had negative earnings in the past year.
STRM had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: STRM reported negative net income in multiple years.
In the past 5 years STRM always reported negative operating cash flow.

1.2 Ratios

STRM has a Return On Assets (-26.10%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -67.47%, STRM is in line with its industry, outperforming 47.22% of the companies in the same industry.
Industry RankSector Rank
ROA -26.1%
ROE -67.47%
ROIC N/A
ROA(3y)-24.63%
ROA(5y)-13.26%
ROE(3y)-50.21%
ROE(5y)-27.25%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

STRM has a Gross Margin (48.98%) which is in line with its industry peers.
In the last couple of years the Gross Margin of STRM has declined.
STRM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.81%
GM growth 5Y-4.29%

More info and screens

1

2. Health

2.1 Basic Checks

STRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STRM has been reduced compared to 1 year ago.
STRM has less shares outstanding than it did 5 years ago.
The debt/assets ratio for STRM is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -4.85, we must say that STRM is in the distress zone and has some risk of bankruptcy.
STRM's Altman-Z score of -4.85 is on the low side compared to the rest of the industry. STRM is outperformed by 69.44% of its industry peers.
STRM has a Debt/Equity ratio of 0.72. This is a neutral value indicating STRM is somewhat dependend on debt financing.
The Debt to Equity ratio of STRM (0.72) is worse than 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF N/A
Altman-Z -4.85
ROIC/WACCN/A
WACC10.17%

2.3 Liquidity

A Current Ratio of 0.46 indicates that STRM may have some problems paying its short term obligations.
STRM's Current ratio of 0.46 is on the low side compared to the rest of the industry. STRM is outperformed by 83.33% of its industry peers.
STRM has a Quick Ratio of 0.46. This is a bad value and indicates that STRM is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of STRM (0.46) is worse than 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.46
Quick Ratio 0.46

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.83% over the past year.
The Revenue for STRM has decreased by -22.50% in the past year. This is quite bad
Measured over the past years, STRM shows a small growth in Revenue. The Revenue has been growing by 0.20% on average per year.
EPS 1Y (TTM)45.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190.7%
Revenue 1Y (TTM)-22.5%
Revenue growth 3Y25.8%
Revenue growth 5Y0.2%
Sales Q2Q%-27.95%

3.2 Future

The Earnings Per Share is expected to grow by 39.37% on average over the next years. This is a very strong growth
Based on estimates for the next years, STRM will show a decrease in Revenue. The Revenue will decrease by -4.24% on average per year.
EPS Next Y93.2%
EPS Next 2Y39.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-11.86%
Revenue Next 2Y-4.24%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

STRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STRM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as STRM's earnings are expected to grow with 39.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.37%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for STRM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STREAMLINE HEALTH SOLUTIONS

NASDAQ:STRM (12/20/2024, 8:00:00 PM)

After market: 3.22 -0.17 (-5.01%)

3.39

+0.24 (+7.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)12-12 2024-12-12/amc
Earnings (Next)N/A N/A
Inst Owners388.9%
Inst Owner Change-4.71%
Ins Owners381.3%
Ins Owner Change7.81%
Market Cap14.31M
Analysts82.86
Price Target1.53 (-54.87%)
Short Float %0.57%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.62%
Min Revenue beat(2)-18.45%
Max Revenue beat(2)1.22%
Revenue beat(4)1
Avg Revenue beat(4)-5.76%
Min Revenue beat(4)-18.45%
Max Revenue beat(4)1.22%
Revenue beat(8)1
Avg Revenue beat(8)-4.89%
Revenue beat(12)5
Avg Revenue beat(12)0.97%
Revenue beat(16)7
Avg Revenue beat(16)1.44%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.77
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.95
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS4.4
BVpS3.3
TBVpS-3.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.1%
ROE -67.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.98%
FCFM N/A
ROA(3y)-24.63%
ROA(5y)-13.26%
ROE(3y)-50.21%
ROE(5y)-27.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.81%
GM growth 5Y-4.29%
F-Score3
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.57%
Cap/Sales 3.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.46
Quick Ratio 0.46
Altman-Z -4.85
F-Score3
WACC10.17%
ROIC/WACCN/A
Cap/Depr(3y)43.1%
Cap/Depr(5y)69.7%
Cap/Sales(3y)7.87%
Cap/Sales(5y)12.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190.7%
EPS Next Y93.2%
EPS Next 2Y39.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-22.5%
Revenue growth 3Y25.8%
Revenue growth 5Y0.2%
Sales Q2Q%-27.95%
Revenue Next Year-11.86%
Revenue Next 2Y-4.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year101.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.48%
OCF growth 3YN/A
OCF growth 5YN/A